- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
- Interventions
- Neuraceq
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
- Interventions
- Nelotanserin, Placebo
- Drug
- Lead sponsor
- Axovant Sciences Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more
- Conditions
- Parkinson's Disease Dementia
- Interventions
- Rivastigmine capsule, Rivastigmine transdermal patch
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
- Conditions
- Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
- Interventions
- Rivastigmine Patch 9.5 cm2
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lewy Body Disease, Parkinson Disease
- Interventions
- E2027
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Sun City, Arizona • Atlantis, Florida • Miami, Florida + 10 more
- Conditions
- Frontotemporal Degeneration (FTD), ALS (Amyotrophic Lateral Sclerosis), Primary Progressive Aphasia (PPA), Familial Frontotemporal Lobar Degeneration (fFTLD), Fronto-temporal Lobar Dementia, Dementia With Lewy Bodies (DLB), Cortical Basal Syndrome (CBS), Alzheimer's Disease (AD), Progressive Supranuclear Palsy(PSP), Parkinson's Disease (PD), Parkinson's Disease Dementia (PDD), Limbic-predominant Age-related TDP-43 Encephalopathy (LATE), Posterior Cortical Atrophy (PCA), Primary Lateral Sclerosis (PLS), Primary Muscular Atrophy (PMA)
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2070
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania